Allevi
Allevi, a brand of 3D Systems, provides an integrated bioprinting platform, including user-friendly desktop bioprinters, a wide variety of bioinks, and intuitive software for life sciences research.
- CEO / Founder
- Frank J. McCaney
- Team Size
- 11-50
- Stage
- Acquired
- Total Funding
- $2.33M
- Latest Round
- Acquired
- Key Investors
- Dreamit, Ben Franklin Technology Partners of Southeastern Pennsylvania, 500 Global, Alumni Ventures Group, Space Angels
Technology & Products
Key Products
Allevi 3D bioprinters (Allevi 1, Allevi 2, Allevi 3) and bioinks (Lifeink®, GelMA) for tissue engineering, organ on a chip, and pharmaceuticals.
Technological Advantage
The company's core advantage is its integrated platform of hardware, software, and a diverse range of bioinks. This simplifies the complex bioprinting workflow. Since its acquisition by 3D Systems, it benefits from enhanced R&D resources, global distribution, and integration with a larger additive manufacturing powerhouse.
Differentiation
Value Proposition
To make bioprinting accessible and easy for researchers by providing a complete, affordable, and user-friendly ecosystem of hardware, software, and biomaterials to accelerate innovation in life sciences.
How They Differentiate
Allevi differentiates itself by focusing on the desktop bioprinting market with an emphasis on affordability, ease of use, and a comprehensive ecosystem. Unlike competitors who may focus on high-end, complex systems or therapeutic development, Allevi provides accessible tools for the research stage. Its integration with 3D Systems also provides a unique advantage in scale and resources.
Market & Competition
Target Customers
Researchers and scientists in academic institutions, pharmaceutical companies, and biotechnology firms engaged in tissue engineering, drug discovery, and regenerative medicine.
Industry Verticals
["Medical","Pharmaceutical","Biotechnology","Academia/Education"]
Competitors
BICO (formerly CELLINK); Aspect Biosystems; Organovo; Xlife sciences
Growth & Milestones
Growth Metrics
Acquired by 3D Systems on May 6, 2021, validating its technology and market traction. As of the acquisition, its products were used in over 380 laboratories in more than 40 countries.
Major Milestones
["2014: Founded as BioBots","2017: Rebranded as Allevi","2018: Launched the Allevi 3, a three-extruder bioprinter","2021: Acquired by 3D Systems for an undisclosed amount"]
Notable Customers
Johnson & Johnson; GlaxoSmithKline (GSK); AbbVie; Stanford University; MIT; University of Sheffield